by AKU | Sep 23, 2020 | Uncategorized
The AKU Society is proud to announce that the European Medicines Agency (EMA), which regulates medications across Europe, has given a positive opinion on the extension of the use of nitisinone to treat AKU. This means the EMA feels that nitisinone can be...
by AKU | Jun 9, 2020 | Uncategorized
Todays blog is written by Dr Andrew Davidson who has recently completed his PhD in AKU and nitisinone. I became a state registered Clinical Scientist in Clinical Biochemistry back in 2008 and following this, like all professionals in the speciality I studied for my...
by AKU | May 21, 2020 | Uncategorized
Last week the AKU Society team attended the 10th European Conference on Rare Diseases 2020 (ECRD 2020), hosted by Eurordis – a charity that represents rare disease patients across Europe. Every two years the ECRD is held in a European country and...
by AKU | Feb 28, 2020 | Uncategorized
It seems like yesterday when I met Robert Gregory. He came to the hospital with his niece who was referred to exclude alkaptonuria (AKU) – before I knew it Robert had registered an AKU Society with the Charity Commission, with me as Medical Director/Co-Founder –...
by AKU | Dec 16, 2019 | Uncategorized
We are delighted to announce that all the data from the SONIA 2 clinical trial has now been analysed and very positive trends have been highlighted. Due to this, SOBI (Swedish Orphan Biovitrum) announced that they are going to apply to the European Medicines...
